2 recruiting, 1 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow James Rubenstein: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma Tafasitamab, Lenalidomide - CNS Lymphoma, Primary Central Nervous System Lymphoma | Phase 1 / Phase 2 | Recruiting | James Rubenstein | 35 | 2022-06-08 | 2026-07-14 |
| Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma Hyperpolarized pyruvate (13C), Magnetic resonance imaging (MRI) - Primary CNS Lymphoma | Phase 1 | Recruiting | James Rubenstein | 26 | 2021-06-29 | 2026-07-14 |
| Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma Lenalidomide, Rituximab - Recurrent/Refractory CNS, Intraocular Lymphoma | Phase 1 | Completed | James Rubenstein | 14 | 2012-12-17 | 2020-08-11 |
Intraocular Lymphoma (1) · Lymphoma (1) · Recurrence (1)
Lenalidomide (2) · Magnetic Resonance Spectroscopy (1) · Rituximab (1) · tafasitamab (1)
United States (3)
R01CA239462 (1)